[1] 周希静. 糖尿病肾病的治疗进展 [J]. 中国中西医结合肾病杂志 2003.doi:10.3969/j.issn.1009-587X.2003.10.001
[2] Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. [J]. Endocrine Reviews 2002, 5(5).
[3] 钱荣立. 糖尿病临床指南 [M]. 北京:北京医科大学出版社 2000.
[4] Barroso L C, Herrera N D, Hueros J C. Incidence of cardiovascular disease and validity of equations of coronary risk in diabetic patients with metabolic syndrome [J]. Medicina Clinica 2007, 128(14).
[5] 刘国良. Ⅱ型糖尿病的早期干预及其处理 [J]. 中国实用内科杂志 2006, 17(12).
[6] UK prospective diabetes study(UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of comp lications in patients with type 2 diabetes(UKPDS 33) [J]. The Lancet 2007.
[7] Dai C, Stolz DB, Bastacky SI, St Arnaud R, Wu C, Dedhar S, Liu Y. Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. [J]. Journal of the American Society of Nephrology: JASN 2006, 8(8).
[8] UK prospective diabetes gtuely(UKPDS) group. No authors listed efficacy of atenololand cap topril in reducing risk of macrovascular and microvascular complications in type 2 diabetes(UKPDS 39) [J]. British Medical Journal 1998, 317(07).
[9] Kim S I, Kwak J H, Zachariah M. TGF activated kinase and TAK binding protein cooperate to mediate TGF212 induced MKK32p38 MAPK activation and stimulation of type I collagen [J]. American Journal of Physiology-Renal Physiology 2007, 291(05).
[10] Huang C C, Jinn Y G, Shyi J S. Insulin and heparin suppress superoxide production in diabetic ratglomeruli stimulated with lowden sity lipoprotein [J]. Kidney International 2001, 59(01).
[11] Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. [J]. Journal of the American Society of Nephrology: JASN 2003, 6(6).
[12] Ritz E, Ogata H, Orth S R. Smoking:a factor p romoting onset and progression of diabetic nephropathy [J]. Diabetes & Metabolism 2000, 26(14).
[13] Bolbrinker J, Markovic S, Wehland M. Expression and response to angiotensin converting enzyme inhibition of matrix metal oproteinases and in renal glomerular damage in young transgenic rats with rennin dependent hypertension [J]. Journal of Pharmacology and Experimental Therapeutics 2006, 316(01).
[14] Gnudi L, Raij L. [J]. Current hypertension reports 2006.
[15] Bohlender J M, Franke S, Stein G. Advanced glycation end products and the kidney [J]. American Journal of Physiology-Renal Physiology 2005, 289(04).
[16] Forbes JM, Thorpe SR, Thallas Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. [J]. Journal of the American Society of Nephrology: JASN 2005, 8(8).
[17] Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ. [J]. The annals of pharmacotherapy 2005.
[18] Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. [J]. Journal of the American Society of Nephrology: JASN 2006, 9(9). |
